On 21 October 2026, Sisram Medical Ltd disclosed a repurchase of 150,000 ordinary shares on the Hong Kong Stock Exchange under its June 2026 general mandate. The buyback, executed at prices ranging from HK$1.825 to HK$1.900 per share, carried a volume-weighted average cost of HK$1.8703, bringing total consideration to approximately HK$0.28 million.

Following the transaction, Sisram’s issued share capital (excluding treasury shares) declined by 0.03% to 467.74 million shares. Treasury holdings increased to 598,400 shares, while the company’s total issued shares remained unchanged at 468.34 million.

The 24 June 2026 mandate authorises Sisram to repurchase up to 46.83 million shares, equivalent to 10% of its then-issued share base. Cumulative repurchases under the mandate have reached 598,400 shares, representing 0.13% of the authorised limit. A 30-day moratorium on new share issues or treasury-share sales is in effect until 20 November 2026, in accordance with Hong Kong Stock Exchange rules.

All repurchase transactions were carried out on the Exchange and, according to the company’s filing, complied with relevant listing and regulatory requirements.